People aged 5–44 regularly dispensed a short-acting beta agonist (SABA) who were not dispensed preventer anytime during the year, among PHO enrolled population. This indicator shows the number and percent of people who were dispensed SABA in at least two quarters in a year and not dispensed preventer in the same year.
High rates of people not receiving any preventer medication despite regular SABA suggests non-adherence to best practice guidelines and suboptimal disease management.
The ARFNZ Adolescent and Adult Asthma guidelines (2020) identifies that good control of asthma shows little use of reliever medication (less than two days per week).
The guideline recommends that ICS or ICS/long-acting beta agonist (LABA) therapy should be introduced if patients have symptoms consistent with a diagnosis of asthma.
Numerator detail
The number of people who were dispensed SABA in two or more quarters and who were not dispensed preventer in the year.
SABA (relievers):
beta-adrenoceptor agonists 209606, 209609, 209611, 209612, 209613, 209614, 209615, 209616, 209617 Salbutamol; 240406, 240407, 240408, 240409, 240410, 240425 Terbutaline Sulphate
Preventers:
Inhaled corticosteroids: 110801,110802, 110803, 110804, 110805, 110806, 110807, 110808, 110809, 110815, 110816, 110825, 110826 & 110827 Beclomethasone dipropionate;
116801, 116802, 116803, 116804 & 116805 Budesonide;
106501, 106502, 106503, 106504, 106505, 106506, 106507, 106508, 106509, 106510, 106511, 106512, 106513, 106514 & 106525 Fluticasone
People dispensed SABA in two or more quarters in a year.
Denominator detail
SABA (relievers): beta-adrenoceptor agonists 209606, 209609, 209611, 209612, 209613, 209614, 209615, 209616, 209617 Salbutamol; 240406, 240407, 240408, 240409, 240410, 240425 Terbutaline Sulphate
Disaggregation
District analysis: By year (2018 –2023), age group (5 –11, 12 –24, 25 44), gender (female, male), ethnic group (Māori, Pacific peoples, European/Other), and Health New Zealand district of domicile. PHO analysis: By year (2023), age group, gender, ethnic group, Primary Health Organisation (PHO) most recently enrolled with (for the relevant year), PHO group (small, medium, medium-large and large).
People who were excluded from analysis include:
- those who aren’t enrolled in a PHO in the calendar year. This allowed us to use the number of PHO-enrolled people as the denominator.
- individuals with missing demographics – that is, those with no recorded value for one or more of the NHI fields used to derive the demographic variables of interest (age, gender, ethnicity and district of domicile). For instance, if there are any missing values for age, they are excluded from all analyses. This approach ensures a consistent denominator throughout the analyses.
Age group is assigned using 30 June of each calendar year as the cutoff point. For example, if a person turned 45 years old on 1 July 2023, they will still be considered 44 years old for 2023.
People who died during the calendar year are excluded from this indicator.
Data is not presented where the number of people in the numerator was less than 10. This is to preserve confidentiality.
In contrast to other atlases, and following advice, we defined regular dispensing as the medication dispensed in two or more quarters of the calendar year. The reason for this difference is that some inhalers can last for more than three months.